Skip to main content
. Author manuscript; available in PMC: 2022 Jun 19.
Published in final edited form as: Leuk Res. 2017 Dec 8;65:20–24. doi: 10.1016/j.leukres.2017.12.001

Fig. 1.

Fig. 1.

Mutation spectrum of 44 pediatric AML patients. Mutations present in primary chemo-resistance (n = 18) and primary chemo-sensitive (n = 26) pediatric AML patients are shown in two separated groups. Cytogenetic subtypes, SNVs and frameshift mutations are shown in colored labels as indicated at the bottom of the figure.